Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: The role of the host

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2414-2421

  Gallagher, D J ^a   Vijai, J ^b   Hamilton, R J ^b   Ostrovnaya, I ^b   Iyer, G ^b,c   Garcia Grossman, I R ^b   Kim, P H ^b   Przybylo, J A ^b   Alanee, S ^b   Riches, J C ^b   Regazzi, A M ^b   Milowsky, M I ^b,c   Offit, K ^b,c   Bajorin, D F ^b,c  

^a ST JAMES S HOSPITAL   (Ireland)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Biomarkers; Carboplatin; Cisplatin; Genetics; Germline; Urothelial

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER PATIENT; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; IC 50; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE;

BIOMARKERS; CARBOPLATIN; CISPLATIN; GENETICS; GERMLINE; UROTHELIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GENOTYPE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84883427236     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt225     Document Type: Article

References (35)

1. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-66.
2. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171-7.
3. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 202-6.
4. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-77.
5. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II-results of EORTC study 30986. J Clin Oncol 2009; 27: 5634-9.
6. Bellmunt J, Albanell J, Paz-Ares L, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002; 95: 751-7.
7. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-81.
8. Kuczyk MA, Bokemeyer C, Serth J, et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995; 31A: 2243-7.
9. Tsuji M, Kojima K, Murakami Y, et al. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 1997; 79: 367-72.
10. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259-64.
11. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13: 1384-90.
12. Stadler WM, Lerner SP, Groshen S, et al. Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ-confined node-negative urothelial bladder cancer (UBC). J Clin Oncol 2009; 27: 15s. (suppl; abstr 5017).
13. Maluf FC, Cordon-Cardo C, Verbel DA, et al. Assessing interactions between mdm- 2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Ann Oncol 2006; 17: 1677-86.
14. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007; 18: 522-8.
15. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011; 22: 139-44.
16. O'Donnell PH, Gamazon E, Zhang W, et al. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet Genomics 2010; 20: 327-37.
17. Garcia-Donas J, Esteban E, Leandro-García LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011; 12: 1143-50.
18. Xu CF, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011; 29: 2557-2564.
19. Campbell MT, Jung J, Philips S, et al. Germ-line single nucleotide polymorphism (SNP) predictors of progression-free survival and overall survival in patients with advanced prostate cancer treated with androgen-deprivation therapy (ADT). J Clin Oncol 2011; 29: 7s. (suppl; abstr 51).
20. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-36.
21. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006; 24: 4534-8.
22. Noach LA, Bosma NB, Jansen J, et al. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994; 29: 425-9.
23. Yuan L, Gu X, Shao J, et al. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol 2010; 29: 611-7.
24. Zhong Z, Yeow WS, Zou C, et al. Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res 2010; 70: 2105-14.
25. Kim CJ, Nishi K, Isono T, et al. Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells. Mol Carcinog 2009; 48: 953-64.
26. Levidou G, Saetta AA, Karlou M, et al. D-type cyclins in superficial and muscleinvasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. J Cancer Res Clin Oncol 2010; 136: 1563-71.
27. Al-Ahmadie H, Iyer G, Lin O, et al. Alterations in genes regulating cell cycle and apoptosis in high-grade urothelial carcinoma. J Clin Oncol 2011; 29: 7s (suppl; abstr 237).
28. Joberty G, Petersen C, Gao L, et al. The cell-polarity protein Par6 links Par3 and atypical protein kinase C to Cdc42. Nat Cell Biol 2000; 2: 531-9.
29. Weyrich P. Kapp K, Niederfellner G, et al. Partitioning-defective protein 6 regulates insulin-dependent glycogen synthesis via atypical protein kinase C. Mol Endocrinol 2004; 18: 1287-300.
30. Qiu RG, Abo A, Steven Martin G. A human homolog of the C. elegans polarity determinant Par-6 links Rac and Cdc42 to PKCzeta signaling and cell transformation. Curr Biol 2000; 10: 697-707.
31. Thomas S, Overdevest JB, Nitz MD, et al. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res 2011; 71: 832-41.
32. Wu X, Ye Y, Rosell R, et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 2011; 103: 817-25.
33. Khoury MJ, McBride CM, Schully SD, et al. The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med 2009; 11: 559-67.
34. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008; 322: 881-8.
35. Hunter DJ, Altshuler D, Rader DJ. From Darwin's finches to canaries in the coal mine-mining the genome for new biology. N Engl J Med 2008; 358: 2760-3.